Overview

A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2023-12-27
Target enrollment:
Participant gender:
Summary
SHR-1316 as Maintenance therapy for limited stage small cell lung cancer without progression after first line platinum based concurrent chemoradiotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Wuhan Union Hospital, China